The goal of this clinical trial is to evaluate the protective effect of metformin on nephrotoxicity of cisplatin in patients with bladder cancer. The main questions it aims to answer are: * To determine protective effect of metformin on structural and functional kidney injury caused by cisplatin in patients with bladder cancer. * To evaluate the safety of combining cisplatin and metformin on patients with bladder cancer
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
78
Metformin 500mg tablets twice daily
faculty of pharmacy Cairo university
Cairo, Egypt
RECRUITINGserum creatinine (SCr)
to assess the nephroprotective effect of metformin against cisplatin induced nephrotoxicity.
Time frame: 12 week
Human Neutrophil gelatinase-associated lipocalin (NGAL)
to assess the nephroprotective effect of metformin against cisplatin induced nephrotoxicity
Time frame: 12 week
Cystatin C
to assess the nephroprotective effect of metformin against cisplatin induced nephrotoxicity
Time frame: 12 week
Estimated glomerular filtration rate (eGFR)
to assess the nephroprotective effect of metformin against cisplatin induced nephrotoxicity
Time frame: 12 week
FBG
to assess the safety of using cisplatin-metformin combination in bladder cancer patients receiving cisplatin
Time frame: 12 week
HbA1C
to assess the safety of using cisplatin-metformin combination in bladder cancer patients
Time frame: 12 week
Body weight
to assess the safety of using cisplatin-metformin combination in bladder cancer patients (monitoring weight loss)
Time frame: 12 week
Body Mass Index
to assess the safety of using cisplatin-metformin combination in bladder cancer patients (monitoring weight loss)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 12 week
Blood pH
to assess the safety of using cisplatin-metformin combination in bladder cancer patients (monitoring lactic acidosis if any)
Time frame: 12 week
Blood Lactate Level
to assess the safety of using cisplatin-metformin combination in bladder cancer patients (monitoring lactic acidosis if any)
Time frame: 12 week